Slide kit outlining a new therapeutic approach for previously untreated chronic lymphocytic leukemia (CLL)

Nils Eckardt, Vice President Medical Affairs, Europe, shares BeiGene’s innovative vision for patients.

A short summary describing a next-generation BTK inhibitor with sustained and potent activity at disease sites and low off-target kinase inhibition.

Chat with BeiGene